GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
| Název česky | GLP-1 agonisté: superiorní pro mozek a tělo u pacientů léčených antipsychotiky? |
|---|---|
| Autoři | |
| Rok publikování | 2022 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | TRENDS IN ENDOCRINOLOGY AND METABOLISM |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub |
| Doi | http://dx.doi.org/10.1016/j.tem.2022.06.005 |
| Klíčová slova | antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia |
| Popis | Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position. |
| Související projekty: |
|